ARTICLE | Product Development
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
November 19, 2024 11:00 PM UTC
Icotrokinra from Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) is the first oral psoriasis therapy since Sotyktu deucravactinib to succeed in Phase III. Although it’s not clear how differentiated on efficacy the IL-23R peptide antagonist will be from other oral therapies in development, the profile does appear favorable against Sotyktu.
The partners reported that icotrokinra, formerly JNJ77242113, met the primary endpoint in a pair of Phase III plaque psoriasis studies. In the 684-patient ICONIC-Lead trial, the placebo-adjusted percentage of patients who achieved an IGA3 score of 0/1 was 56.4, while the placebo-adjusted PASI 90 score was 45.2%. Results have yet to be reported from the secondary endpoints of PASI 75 and PASI 100…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654249/new-oral-psoriasis-mechanism-from-protagonist-j-j-yields-competitive-phase-iii-data